Cedric Hermans and Glenn Pierce On The Essential Role of A Positive Reinvestment Cycle in Hemophilia
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, shared on LinkedIn:
”Hemophilia stands out among rare diseases for its remarkable therapeutic progress, a success built on decades of innovation, scientific discovery, and investment.
From the cloning of FVIII and FIX genes to the arrival of gene therapy, each milestone has transformed lives.
Global advocacy by WFH, EAHAD, and NBDF has been key to ensuring access and safety.
Yet, sustaining this progress requires continued commitment and investment, so that every person with hemophilia can benefit from the full promise of science.”
Read the full article here.
Article: Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle
Authors: Cedric Hermans, Glenn F Pierce
Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar